Morphological predictors of BRCA1 germline mutations in young women with breast cancer

Department of Pathology, Genetic Epidemiology Laboratory, Victoria, Carlton, Australia.
British Journal of Cancer (Impact Factor: 4.84). 02/2011; 104(6):903-9. DOI: 10.1038/bjc.2011.41
Source: PubMed


Knowing a young woman with newly diagnosed breast cancer has a germline BRCA1 mutation informs her clinical management and that of her relatives. We sought an optimal strategy for identifying carriers using family history, breast cancer morphology and hormone receptor status data.
We studied a population-based sample of 452 Australian women with invasive breast cancer diagnosed before age 40 years for whom we conducted extensive germline mutation testing (29 carried a BRCA1 mutation) and a systematic pathology review, and collected three-generational family history and tumour ER and PR status. Predictors of mutation status were identified using multiple logistic regression. Areas under receiver operator characteristic (ROC) curves were estimated using five-fold stratified cross-validation.
The probability of being a BRCA1 mutation carrier increased with number of selected histology features even after adjusting for family history and ER and PR status (P<0.0001). From the most parsimonious multivariate model, the odds ratio for being a carrier were: 9.7 (95% confidence interval: 2.6-47.0) for trabecular growth pattern (P=0.001); 7.8 (2.7-25.7) for mitotic index over 50 mitoses per 10 high-powered field (P=0.0003); and 2.7 (1.3-5.9) for each first-degree relative with breast cancer diagnosed before age 60 years (P=0.01).The area under the ROC curve was 0.87 (0.83-0.90).
Pathology review, with attention to a few specific morphological features of invasive breast cancers, can identify almost all BRCA1 germline mutation carriers among women with early-onset breast cancer without taking into account family history.


Available from: Graham G Giles
  • Source
    • "BRCA1/2 carriers more often present with early-onset breast–ovarian cancer (see review by Robson, 2004) and bilateral breast cancer (Metcalfe et al., 2011a, 2011b). BRCA1-associated tumors are large, display high proliferation, and poor differentiation; and triple-negative receptors (Anders et al., 2008), associated as a rule with poor prognosis (Zhou and Recht, 2004; Young et al., 2009; Hall et al., 2010; Varga et al., 2010; Comen et al., 2011; Smith et al., 2011; Southey et al., 2011). The overall survival rate in BRCA1-associated breast cancer patients compared to agematched sporadic breast cancer patients varies among studies , some reporting a poorer prognosis in BRCA1 carriers compared to noncarriers and others showing a similar survival rate (Robson et al., 1998, 1999; Lee et al., 2010; see review by van der Groep et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This article presents the complexity of prenatal genetic diagnosis and preimplantation genetic diagnosis for hereditary breast-ovarian cancer syndrome. These issues are discussed using a case report to highlight the genetic counseling process, together with decision-making considerations, in light of the clinical, psychological, and ethical perspectives, of both the mutation carriers and health professionals; and the health policy regarding these procedures in Israel compared to several European countries.
    Genetic Testing and Molecular Biomarkers 06/2014; 18(7). DOI:10.1089/gtmb.2013.0513 · 1.46 Impact Factor
  • Source
    • "Missing data for tumour morphology features (average 4 (0.5%) missing per feature) were estimated using multiple imputation, made possible by the correlations between different morphological features (see Southey et al, 2011 and Dite et al, 2012 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Population-based studies of breast cancer have estimated that at least some PALB2 mutations are associated with high breast cancer risk. For women carrying PALB2 mutations, knowing their carrier status could be useful in directing them towards effective cancer risk management and therapeutic strategies. We sought to determine whether morphological features of breast tumours can predict PALB2 germline mutation status. Methods: Systematic pathology review was conducted on breast tumours from 28 female carriers of PALB2 mutations (non-carriers of other known high-risk mutations, recruited through various resources with varying ascertainment) and on breast tumours from a population-based sample of 828 Australian women diagnosed before the age of 60 years (which included 40 BRCA1 and 18 BRCA2 mutation carriers). Tumour morphological features of the 28 PALB2 mutation carriers were compared with those of 770 women without high-risk mutations. Results: Tumours arising in PALB2 mutation carriers were associated with minimal sclerosis (odds ratio (OR)=19.7; 95% confidence interval (CI)=6.0–64.6; P=5 × 10−7). Minimal sclerosis was also a feature that distinguished PALB2 mutation carriers from BRCA1 (P=0.05) and BRCA2 (P=0.04) mutation carriers. Conclusion: This study identified minimal sclerosis to be a predictor of germline PALB2 mutation status. Morphological review can therefore facilitate the identification of women most likely to carry mutations in PALB2.
    British Journal of Cancer 06/2013; 109(1):154-163. DOI:10.1038/bjc.2013.295 · 4.84 Impact Factor
  • Source
    • "HUMAN MUTATION, Vol. 00, No. 0, 1–11, 2012 (1) mitotic index over 50 per 10 hpf, (2) malignant nuclear grade, (3) little or no tubule formation, (4) a trabecular growth pattern, (5) pushing margins (>50%), (6) circumscribed growth pattern, (7) a syncytial growth pattern, (8) necrosis, and (9) moderate or intense lymphocytic infiltrate [Armes et al., 1998; Southey et al., 2011]. These cases were screened for genetic variants in a 116 bp highly evolutionary conserved region (ECR) in the BRCA1 3 UTR extending from nucleotides 235 to 351. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in the BRCA1 gene confer a substantial increase in breast cancer risk, yet routine clinical genetic screening is limited to the coding regions and intron-exon boundaries, precluding the identification of mutations in noncoding and untranslated regions (UTR). As 3'UTR mutations can influence cancer susceptibility by altering protein and microRNA (miRNA) binding regions, we screened the BRCA1 3'UTR for mutations in a large series of BRCA-mutation negative, population and clinic-based breast cancer cases, and controls. Fifteen novel BRCA1 3'UTR variants were identified, the majority of which were unique to either cases or controls. Using luciferase reporter assays, three variants found in cases, c.(*) 528G>C, c.(*) 718A>G, and c.(*) 1271T>C and four found in controls, c.(*) 309T>C, c.(*) 379G>A, c.(*) 823C>T, and c.(*) 264C>T, reduced 3'UTR activity (P < 0.02), whereas two variants found in cases, c.(*) 291C>T and c.(*) 1139G>T, increased 3'UTR activity (P < 0.01). Three case variants, c.(*) 718A>G, c.(*) 800T>C, and c.(*) 1340_1342delTGT, were predicted to create new miRNA binding sites and c.(*) 1340_1342delTGT caused a reduction (25%, P = 0.0007) in 3'UTR reporter activity when coexpressed with the predicted targeting miRNA, miR-103. This is the most comprehensive identification and analysis of BRCA1 3'UTR variants published to date.
    Human Mutation 12/2012; 33(12). DOI:10.1002/humu.22159 · 5.14 Impact Factor
Show more